MoonLake posts Q3 2026 loss of $79.5 million and files BLA for sonelokimab
MoonLake Immunotherapeutics reported a net loss of $79.5 million for the quarter ended September 30, 2026. The company held $498.5 million in cash and short‑term investments and said its cash runway now extends to mid‑2028. It filed a biologics license application with the FDA for sonelokimab to treat moderate‑to‑severe hidradenitis suppurativa and disclosed ongoing Phase 3 trials in psoriatic arthritis, palmoplantar pustulosis and other inflammatory diseases.
Why it matters
The widened loss reflects higher R&D spending, which may affect near‑term cash burn but the sizable cash balance gives the firm runway to complete pivotal trials and potentially launch the product in 2027, according to the company’s guidance.
Key facts
- 1Net loss for Q3 2026 was $79.5 million, or $0.93 per share (basic and diluted). tradingview.com
- 2Cash, cash equivalents and short‑term marketable debt securities totaled $498.5 million as of September 30, 2026. tradingview.com
- 3Research and development expenses for the quarter were $68.9 million, up from $50.2 million in the prior quarter. tradingview.com
- 4MoonLake submitted a biologics license application to the FDA on September 30, 2026 for sonelokimab in hidradenitis suppurativa. tradingview.com
- 5The company expects its cash runway to last until mid‑2028. tradingview.com
- 6The Q3 net loss was $79.54 million, compared with $61.80 million a year earlier. rttnews.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.